1.75
+0.185(+11.82%)
Currency In USD
| Previous Close | 1.57 |
| Open | 1.69 |
| Day High | 2.18 |
| Day Low | 1.57 |
| 52-Week High | 4.15 |
| 52-Week Low | 1.04 |
| Volume | 45.18M |
| Average Volume | 159,665 |
| Market Cap | 41.52M |
| PE | -0.62 |
| EPS | -2.88 |
| Moving Average 50 Days | 1.26 |
| Moving Average 200 Days | 1.65 |
| Change | 0.22 |
If you invested $1000 in Rein Therapeutics Inc. (RNTX) since IPO date, it would be worth $841.98 as of November 03, 2025 at a share price of $1.785. Whereas If you bought $1000 worth of Rein Therapeutics Inc. (RNTX) shares 0 years ago, it would be worth $841.98 as of November 03, 2025 at a share price of $1.785.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
GlobeNewswire Inc.
9 hours ago
FDA lifts clinical hold following review of Company’s Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites.Early data suggests that LTI-03 may not only slow fibrosis but also prom
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
GlobeNewswire Inc.
Oct 09, 2025 11:30 AM GMT
EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trialTrial will evaluate LTI-03, a first-in-class therapy designed to both reduce lung scarring and promote repair AUSTIN, Texas, Oct. 09, 2025 (GLO
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
GlobeNewswire Inc.
Sep 17, 2025 11:30 AM GMT
Peer-reviewed publication highlights potential breakthrough anti-fibrotic properties of LTI-03 in lung tissue from IPF patientsAUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company